RELAPSED/REFRACTORY MULTIPLE MYELOMA-TRANSFORMED PLASMA-CELL LEUKEMIA SUCCESSFULLY TREATED WITH DARATUMUMAB FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION

Relapsed/refractory multiple myeloma-transformed plasma-cell leukemia successfully treated with daratumumab followed by autologous stem cell transplantation

Daratumumab is a humanized anti-CD38 IgG1 monoclonal antibody which could be used for multiple myeloma (MM).MM with plasma-cell leukemia (PCL) transformation is highly aggressive and is resistant to conventional therapy.Novel therapeutics are needed for PCL, and daratumumab may play role.We report a case of relapsed/refractory multiple myeloma (RRM

read more